NCT00507117

Brief Summary

Patients often have difficulty sleeping during overnight sleep testing in a lab environment. The purpose of this study is to determine if taking a sleep aid will improve sleep and therefore the quality of the sleep study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Mar 2007

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2007

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

July 23, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 25, 2007

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2007

Completed
Last Updated

November 30, 2007

Status Verified

October 1, 2007

First QC Date

July 23, 2007

Last Update Submit

November 29, 2007

Conditions

Keywords

Obstructive Sleep ApneaPolysomnographyNon-benzodiazepine hypnotics

Outcome Measures

Primary Outcomes (7)

  • diagnostic yield of PSG

    during overnight study

  • total sleep time

    during overnight study

  • wake after sleep onset

    during overnight study

  • sleep latency

    during overnight study

  • sleep efficiency

    during overnight study

  • total arousal index

    during overnight study

  • respiratory disturbance index at highest CPAP level

    during overnight study

Secondary Outcomes (1)

  • Respiratory Disturbance Index

    during overnight study

Study Arms (1)

PSG

ACTIVE COMPARATOR
Drug: LunestaDrug: Placebo control

Interventions

Lunesta 3mg prior to PSG

PSG

matching placebo

PSG

Eligibility Criteria

Age18 Years - 64 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • All adult patients aged 18-65, evaluated by a sleep medicine provider in the Walter Reed Army Medical Center Sleep Disorders Clinic, who are referred for PSG for suspected Obstructive Sleep Apnea Syndrome

You may not qualify if:

  • Pregnancy
  • Liver dysfunction or history of EtOH abuse
  • Concomitant use of benzodiazepines, narcotics or ketozonazole
  • Decompensated CHF
  • CVA within 3 months
  • Uncontrolled psychiatric disorders
  • Patients \< 18 years old
  • Patients over 65

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Walter Reed Army Medical Center

Washington D.C., District of Columbia, 20307, United States

Location

Related Publications (3)

  • Lettieri CJ, Eliasson AH, Andrada T, Khramtsov A, Kristo DA. Does zolpidem enhance the yield of polysomnography? J Clin Sleep Med. 2005 Apr 15;1(2):129-31.

    PMID: 17561625BACKGROUND
  • Lettieri CJ, Collen JF, Eliasson AH, Quast TM. Sedative use during continuous positive airway pressure titration improves subsequent compliance: a randomized, double-blind, placebo-controlled trial. Chest. 2009 Nov;136(5):1263-1268. doi: 10.1378/chest.09-0811. Epub 2009 Jun 30.

  • Lettieri CJ, Quast TN, Eliasson AH, Andrada T. Eszopiclone improves overnight polysomnography and continuous positive airway pressure titration: a prospective, randomized, placebo-controlled trial. Sleep. 2008 Sep;31(9):1310-6.

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Interventions

Eszopiclone

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Intervention Hierarchy (Ancestors)

PiperazinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPyrazinesPyridines

Study Officials

  • Christopher J Lettieri, MD

    Walter Reed Army Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
FED

Study Record Dates

First Submitted

July 23, 2007

First Posted

July 25, 2007

Study Start

March 1, 2007

Study Completion

October 1, 2007

Last Updated

November 30, 2007

Record last verified: 2007-10

Locations